Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 3:25 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 1,745 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Formulation #2 Clear all

Conditions: Amyotrophic Lateral Sclerosis
Interventions: GDC-0134, Placebo, Rabeprazole, Midazolam, Caffeine; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 8
States / cities: San Francisco, California • Jacksonville, Florida • Miami, Florida + 5 more

Conditions: Hereditary Thrombotic Thrombocytopenic Purpura (TTP)
Interventions: Recombinant ADAMTS13; Drug
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 3
States / cities: Dublin, Ohio • Portland, Oregon • Houston, Texas

Conditions: Type 2 Diabetes
Interventions: PATAS Trifluoroacetate, Placebo; Drug
Lead sponsor: AdipoPharma LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Chandler, Arizona • Miami, Florida • Port Orange, Florida

Conditions: Cystic Fibrosis
Interventions: VNZ/TEZ/D-IVA; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Hand Eczema
Interventions: Ruxolitinib cream, Vehicle; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 23
States / cities: Phoenix, Arizona • Fountain Valley, California • Huntington Beach, California + 18 more

Conditions: Schizophrenia
Interventions: Iloperidone crystalline formulation, Iloperidone microparticle formulation, Oral iloperidone; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Glendale, California • Philadelphia, Pennsylvania

Conditions: Influenza, Human
Interventions: Flu mRNA (Formulation B1), Flu mRNA (Formulation B3), Flu mRNA(Formulation A), Comparator 1, Comparator 2, Comparator 3; Biological · Combination Product
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 971 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 15
States / cities: Guntersville, Alabama • Canoga Park, California • Walnut Creek, California + 12 more

Conditions: Keratocystic Odontogenic Tumor
Interventions: vismodegib; Drug
Lead sponsor: NYU College of Dentistry; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Cancer
Interventions: eRapa (encapsulated rapamycin); Drug
Lead sponsor: Rapamycin Holdings, Inc. dba Emtora Biosciences; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Glabellar Frown Lines
Interventions: AI-09, Vehicle; Biological
Lead sponsor: Eirion Therapeutics Inc.; Industry
Eligibility: 20 Years to 70 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 4
States / cities: Boca Raton, Florida • Miami, Florida • New Brighton, Minnesota + 1 more

Conditions: Breast Cancer
Interventions: adenovirus-mediated human interleukin-12; Biological
Lead sponsor: Max Sung; Other
Eligibility: 18 Years and older · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Inborn Errors of Bile Acid Synthesis
Interventions: Cholic acid; Drug
Lead sponsor: Mirum Pharmaceuticals, Inc.; Industry
Eligibility: Not listed
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Tetanus, Diphtheria, Pertussis, Whooping Cough
Interventions: Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed Formulation 1, Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 2, Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 3, Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 4, Licensed Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Licensed Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 10 Years and older
Enrollment: 1,363 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 20
States / cities: Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 16 more

Conditions: Healthy
Interventions: fluoxetine HCL 40 mg capsules; Drug
Lead sponsor: Ranbaxy Laboratories Limited; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute
Interventions: Azacitidine, Pevonedistat; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 23
States / cities: Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 19 more

Conditions: Anthrax, Anthrax Immunisation
Interventions: AV7909; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Blood Pressure
Interventions: MENT or placebo; Drug
Lead sponsor: Population Council; Other
Eligibility: 18 Years to 40 Years · Male only
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: COVID-19
Interventions: SARS-CoV-2 mRNA vaccine formulation 1, SARS-CoV-2 mRNA vaccine formulation 2, SARS-CoV-2 mRNA vaccine formulation 3, Placebo (0.9% normal saline); Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 182 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 12
States / cities: Rolling Hills Estates, California • Hollywood, Florida • Miami, Florida + 9 more

Conditions: Hospice Informal Caregivers
Interventions: Problem Solving Therapy; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 514 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Colorectal Neoplasms
Interventions: CPX-1 (Irinotecan HCl:Floxuridine) Liposome Injection; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 11
States / cities: Greenbrae, California • Washington D.C., District of Columbia • Coral Springs, Florida + 8 more

Conditions: Photoaging, Wrinkle, Skin Laxity
Interventions: Hybrid Fractional Laser, Facial Cleanser, Facial Moisturizer, Sunscreen; Procedure · Other
Lead sponsor: Revision Skincare; Industry
Eligibility: 35 Years to 65 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Atlanta, Georgia • Dallas, Texas

Conditions: Influenza
Interventions: GSK2340274A, GSK2340273A, Saline placebo; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 1,343 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 10
States / cities: Huntsville, Alabama • Jacksonville, Florida • Miami, Florida + 7 more

Conditions: Complication of Transplant
Interventions: Prograf, Tacrolimus, Sandoz, Tacrolimus, Reddy Laboratory, Tacrolimus, Mylan, Tacrolimus, Accord, Tacrolimus, Pancea Biotech Limited; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
Interventions: Biospecimen Collection, Computed Tomography, Fluorouracil, Gemcitabine, Irinotecan, Irinotecan Sucrosofate, Leucovorin, Nab-paclitaxel, Panitumumab, Questionnaire Administration; Procedure · Drug · Biological + 1 more
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 274
States / cities: Anchorage, Alaska • Phoenix, Arizona • Fayetteville, Arkansas + 207 more

Search by objective public record fields.

A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis

Phase 1 Dose Escalation, Single Dose Study to Assess Safety and Pharmacokinetics of BAX930 in Hereditary Thrombotic Thrombocytopenic Purpura (TTP)

A Study of PATAS Using Single Ascending Doses in Healthy Volunteers and Multiple Ascending Doses in Diabetic Subjects

A Study To Evaluate the Relative Bioavailability, Food Effect, and Dose Proportionality of a Granule Formulation of Vanzacaftor/Tezacaftor/Deutivacaftor(VNZ/TEZ/D-IVA)

Topical Ruxolitinib Evaluation in Chronic Hand Eczema

Safety, Tolerability, and Pharmacokinetics of Iloperidone Depot in Schizophrenic Patients

A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above

A Phase 2, Single-center, Single-arm, Open Label Trial of Vismodegib in Patients With Keratocystic Odontogenic Tumors

Trial of eRapa in Prostate Cancer Patients

AI-09 In Subjects With Glabellar Lines, GL-101

Gene Therapy in Treating Women With Metastatic Breast Cancer

Efficacy of To Be Marketed (TBM) Cholic Acid Capsules Used to Treat Children With Inborn Errors of Bile Acid Synthesis

Study of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed in Healthy Subjects

Bioequivalence Study of Fluoxetine HCL 40 mg Capsules Under Fasting Conditions

An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)

Anthrax AV7909 Liquid vs Lyophilized

A Two-part Trial Assessing the Effects of 7α-methyl-19-nortestosterone (MENT) on Blood Pressure in Normal Men: an Open-label Pilot Study Followed by a Randomized, Double-blind, Placebo-controlled Study

Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older

Hospice Problem Solving Intervention

Multicenter Study Of CPX-1 (Irinotecan HCl: Floxuridine) Liposome Injection In Patients With Advanced Colorectal Cancer

Evaluating Procedure Pairing of a Post-Procedure Cream Versus a Comparator in Patients Treated With a Hybrid-Fractional Laser for Facial Rejuvenation

Safety and Immunogenicity of H1N1 Vaccines in Adults Aged 18 Years and Older

Conversion From Brand to Generic Tacrolimus in High Risk Transplant Recipients

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations